<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35661900</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8421</ISSN><JournalIssue CitedMedium="Internet"><Volume>369</Volume><PubDate><Year>2022</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroimmunology</Title><ISOAbbreviation>J Neuroimmunol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.</ArticleTitle><Pagination><StartPage>577900</StartPage><MedlinePgn>577900</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2022.577900</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-5728(22)00095-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cystatin C has neuroprotective and immunomodulatory effects on the central nervous system. However, the role of cerebrospinal fluid (CSF) cystatin C in anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDARE) remains unknown.</AbstractText><AbstractText Label="METHODS">In this study, CSF levels of cystatin C were determined in 73 patients with anti-NMDARE; 496 patients with other neurological diseases, comprising 108 with neuromyelitis optica, 77 with multiple sclerosis, 71 with schizophrenia, 68 with cryptococcus meningitis or meningoencephalitis, 43 with tuberculous meningitis or meningoencephalitis, 43 with bacterial meningitis or meningoencephalitis (BM), 35 with Guillain-Barr&#xe9; syndrome, 23 with spinal cord injury (SCI), 14 with amyotrophic lateral sclerosis (ALS), and 14 with idiopathic epilepsy; and 136 control patients with non-inflammatory diseases. The associations of CSF cystatin C with anti-NMDARE and its clinical parameters were evaluated.</AbstractText><AbstractText Label="RESULTS">CSF cystatin C levels were significantly lower in patients with anti-NMDARE than in patients with BM, SCI, and ALS, especially among those with poor functional status (modified Rankin Scale [mRS] &#x2265;4). CSF cystatin C levels were also significantly lower in anti-NMDARE patients with poor functional status (mRS &#x2265;4) than in those with good functional status (mRS &lt;4). CSF cystatin C levels were significantly associated with mRS scores and CSF white blood cell counts in anti-NMDARE patients.</AbstractText><AbstractText Label="CONCLUSIONS">CSF levels of cystatin C are decreased in anti-NMDARE patients and negatively associated with disease severity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Baohua</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory(,) The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Minqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory(,) The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Data Center(,) The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yanyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Stomatology(,) The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory(,) The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zhengqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Yaqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: shuyaq@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuroimmunol</MedlineTA><NlmUniqueID>8109498</NlmUniqueID><ISSNLinking>0165-5728</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060426" MajorTopicYN="Y">Anti-N-Methyl-D-Aspartate Receptor Encephalitis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="Y">Cystatin C</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="N">Meningoencephalitis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35661900</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2022.577900</ArticleId><ArticleId IdType="pii">S0165-5728(22)00095-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>